Introduction {#s1}
============

Spirochetes of the genus *Borrelia* are divided into three major groups according to the vector and/or the pathology they can cause. Bacteria of the first group such as *B. duttonii* and *B. hermsii* are responsible for relapsing fevers, transmitted by soft ticks (*Argasidae*). Bacteria of the second group, such as *B. burgdorferi* and *B. afzelii* are the agents of Lyme disease, transmitted by hard ticks (*Ixodidae*). The third group includes species phylogenetically close to species of the first group, but transmitted by hard ticks, including *B. theileri* affecting cattle, *B. lonestari* affecting deer and *B. miyamotoi* affecting rodents (*Apodemus argenteus, Apodemus flavicollis, Myodes glareolus, Peromyscus leucopus*) and birds (*Cardinalis cardinalis, Parus major, Carduelis chloris*), which serve as intermediate reservoirs before humans ([@B1]--[@B3]).

Lyme disease, or Lyme borreliosis, is the most common tick-borne disease in the northern hemisphere. In Europe, the bacteria belonging to the complex *Borrelia burgdorferi sensu lato* (*B. burgdorferi s.l*.) are transmitted by the ticks of the genus *Ixodes*. The geographical distribution of Lyme disease is linked to that of the vector, mostly found in cool and humid habitats, such as forests. In France, the incidence of the disease varies according to the region studied, increases with years and is now observed on the whole mainland territory with an incidence of 104 cases per 100,000 inhabitants in 2018 ([@B4], [@B5]). However, the lack of physicians\' obligation to report cases of Lyme disease makes difficult to determine its precise incidence and location. Furthermore the tick bite is often unnoticed by the patient. The primary stage of the disease is characterized by erythema migrans, a specific sign but not constant. Patients presenting with later stage of Lyme disease suffer from subjective or non-specific polymorphic signs and symptoms which may persist after the end of currently recommended antibiotic treatments. In most of the cases, there is asthenia, possibly disabling, with pain which may be localized in joints, muscles, bones or of neurologic origin. Pain is often migrating. Many patients complain about neurocognitive disorders. Most of the patients present with objective signs from different organs or systems (neurologic, rheumatologic, cutaneous, cardiac, visual...) but these signs are not specific and may be observed in other diseases. Lyme disease serology may be negative ([@B6]). Thus, physicians lack accurate diagnostic tests to better investigate the possible causes of these nonspecific syndromes. To further complicate the issue, it has been shown that some of these patients may suffer from other co-infections due to bacteria or parasites such as *Babesia*. Different names have been proposed to define these signs and symptoms, often mentioned as "post-treatment Lyme disease syndrome," PTLDS ([@B7]). In France, the denomination recognized by the High Authority for Health (Haute Autorité de Santé, HAS) in the official French Recommendation of Good Practice (June 2018) is "persistent polymorphic syndrome possibly due to a tick bite," (SPPT) ([@B8]). The difference between SPPT and PTLDS is that a diagnosis of Lyme disease has not to be proven and patients may have not been treated. It is now established that various species of *Borrelia* may be isolated from humans. *Borrelia miyamotoi*, discovered more than two decades ago, has been isolated from ticks and from patients in various regions of the world. Its real incidence in populations is not yet established.

*B. miyamotoi* was first described in 1995, isolated from ticks of the genus *Ixodes persulcatus* ([@B9]). Later, it was also observed in other tick species such as *I. scapularis, I. Pacificus*, and *I. ricinus* ([@B10]). Its DNA has shown similarities with other *Borrelia* species. It was named *Borrelia miyamotoi* sp. nov. (reference strain: HT31) and has been first classified with the *Borrelia* involved in relapsing fevers ([@B9]). However, further studies have shown that *B. miyamotoi* could provide in some patients signs and symptoms similar to Lyme disease. In 2011, a Russian team highlighted for the first time the presence of *B. miyamotoi* in humans. A large proportion of patients showed signs and symptoms similar to those caused by *B. burgdorferi s.l*., including fever, headache, myalgia and arthralgia ([@B11]). The authors also found a high incidence of *B. miyamotoi* in the study area. Infections with *B. miyamotoi* seemed more severe than those observed with *B. burgdorferi* or *B. garinii*. In a study by Lee et al. ([@B12]), a highly conserved 357-bp segment of 16S rDNA gene of *B. burgdorferi s.l*. plus the correspondent 358 bp-segment of *B. miyamotoi* were amplified by nested PCR (single pair of primers). Amplicons were used as templates for direct Sanger DNA sequencing. This technique allowed, in winter, to detect spirochetemia in 14 patients. Among these, the bacterium involved was *B. miyamotoi* in four cases and a combinaison of *B. miyamotoi* and *B. burgdorferi* in one case. In immunocompromised patients, *B. miyamotoi* infection caused meningoencephalitis in the United States and in Europe in the Netherlands ([@B13], [@B14]). In France, the first study on *B. miyamotoi* was carried out in 2014 on ticks and rodents ([@B15]), demonstrating that 3% of the ticks and 5.55% of the rodents were infected with *B. miyamotoi*. Strain sequencing showed the same genotype not only in ticks, rodents but also in one Dutch patient reported by Hovius et al. ([@B14]). In Japan the same year, two publications showed that *B. miyamotoi* could be present in patients presenting with signs and symptoms suggesting Lyme disease ([@B16], [@B17]). Subsequently, *B. miyamotoi* has also been detected in other European countries such as Belgium and England ([@B18], [@B19]). In a study conducted in New York state using multiplex real-time PCR on 796 clinical specimens (blood and CSF), *B. miyamotoi* was found in eight cases ([@B20]). The frequency of *B. miyamotoi*, as a human pathogen, as well as the severity of some related signs and symptoms such as meningoencephalitis, make prevention, diagnosis and treatment of this infection essential ([@B21]). Furthermore, *B. Miyamotoi* may be resistant to some antibiotics such as amoxicillin, at least *in vitro* and has the ability to bypass the body\'s immune mechanisms, such as the complement by means of a surface protein, a factor H-binding protein, termed CbiA (complement binding and inhibitory protein A) ([@B22]--[@B24]). The local immune response is influenced by the tick, which secretes a multitude of immunosuppressive salivary factors that target the organism defense molecules. The subsequent immune reaction is delayed or incomplete thanks to the intervention of glycoproteins, called "evasins," which will bind to the chemokines secreted by the host, inhibiting their actions ([@B25]). A known problem of infections caused by (some, if needed) strains of group *Borrelia s.l*. is the reappearanceor persistence of signs and symptoms after a classical treatment ([@B26], [@B27]). Recently, a study conducted in Russia, confirmed the presence of *B. miyamotoi* in 70 of 473 patients at the early stage of signs and symptoms occurring after a tick bite ([@B28]). This study showed that the median time for detection of *B. miyamotoi* in blood was 4 days after inoculation. No human case of *B. miyamotoi* has been described in France yet.

The purpose of this study, carried out in a population different from that studied in 2018 by Karan et al. ([@B28]), was to look for *B. miyamotoi* in the blood of patients living in France and suffering from a persistent polymorphic syndrome possibly due to a tick bite ([@B7], [@B8]). In case of positive tests, we obtained a first approximation of the incidence of the infection. Due to numerous positive tests, the study was further completed with a clinical evaluation. A standardized questionnaire was sent to the patients detected positive and to their physicians to obtain information about their medical history and clinical presentation.

Patients and Methods {#s2}
====================

Patients and Samples
--------------------

Blood samples were drawn from two groups of people. A control group was made up of healthy students of the University of Angers, not expressing signs or symptoms and located in a rural region of France (*n* = 24). The second group included patients, expressing signs and symptoms compatible with a persistent polymorphic syndrome possibly due to a tick bite and living in different regions of France (*n* = 824). These signs and symptoms included a range of conditions associated with fatigue, sleep disturbance, neurological/musculoskeletal pain, and cognitive dysfunction, lasting for at least 6 months. A questionnaire was used, including the main signs and symptoms usually observed during SPPT/PTLDS ([@B7], [@B8]).

Five milliliters of blood were collected by venous puncture in tubes with EDTA as anti-coagulant, before any antibiotic treatment and were sent in Vacutainer® K2 tubes.

Selection of Primers
--------------------

To allow the detection of *B. miyamotoi*, primers targeting the gene *glpQ* (Accession [KU845211.1](KU845211.1)) of *B. miyamotoi* and framing of 94 bp portion of gene were used ([@B29]) ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). The primers used in this study were derived from an existing publication by Reiter et al. who developed a new PCR approach for the detection of *B. miyamotoi* in ticks ([@B30]). Alignment of the sequence of interest of *B. miyamotoi* with the same portions of sequences in the genome of other *Borrelia* species confirms the specificity of the primers ([Figure 1](#F1){ref-type="fig"}). In order to be more sensitive, a PCR simplex kit specific for *B. miyamotoi* was used, to avoid the loss of sensitivity common with multiplex kits.

###### 

Sequences of the primers used for *B. miyamotoi* PCR and sequences of housekeeping gene (GAPDH) primers.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  **Target**             **Gene**                                         **Primers**                               **Probes**
  ---------------------- ------------------------------------------------ ----------------------------------------- ---------------------------------------
  *Borrelia miyamotoi*   Glycerophosphodiester phosphodiesterase *glpQ*   F 5′ TGCACAATTATTTCCCAATCGA 3′\           
                                                                          R 5′ TTCACTGAGACTTAGTGATTTAAGTTCAGTT 3′   

  Human                  *GAPDH*                                          F 5′ GAAGGTGAAGGTCGGAGT 3′\               5′-6-FAM CAAGCTTCCCGTTCTCAGCC-BHQ1-3′
                                                                          R 5′ GAAGATGGTGATGGGATTTC 3′              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

![Several sequences of the *glpQ* gene portion used for the detection of *B. miyamotoi* and belonging to other species of the recurrent fever group of *Borreliae* are aligned and compared. Bold and underlined: primers for the target *B. miyamotoi*. The *glpQ* gene, in the current state of the art and genome annotations has not been described in *Borrelia* species other than those of the recurrent fever group. Highlighted: the sequence differences of some recurrent fever *Borrelia* compared to that of *B. miyamotoi*. The following sequences are aligned: *B. miyamotoi* (D43777.1), *B. hermsii* (DQ855539.1), *B. lonestari* (AY368275.1), *B. duttoni* (DQ346787.1), *B. microti* (EU914144.1), *B. recurrentis* (DQ346781) .1), *B. turcica* (AB529430.1), *B. theileri* (KF569938.1)*, B. persica* (AY530742.1)*, B. venezuelensis (*MG651651.1)*, B. hispanica* (GU357572.1)*, B. parkeri* (MH704900.1)*, B. crocidurae* (JX292940.1). The regions of the primers are very different between species.](fmed-07-00055-g0001){#F1}

Robustness of PCR Mixes
-----------------------

The portion of the *glpQ* sequence of *B. miyamotoi* was synthesized and introduced into a plasmid to obtain a control DNA and facilitate its multiplication. This control DNA was used to validate the amplification mix. Serial dilution of the plasmid was performed and amplified to determine the robustness parameters of the *B. miyamotoi* PCR kit: the limit of detection (LOD), the limit of quantification (LOQ), the repeatability and the reproducibility ([Table 2](#T2){ref-type="table"}).

###### 

Characteristics of the *B. miyamotoi* PCR kit.

  **PCR Mix**            **LOD**   **LOQ**   **Repeatability**   **Reproducibility**                         
  ---------------------- --------- --------- ------------------- --------------------- ------ ------- ------ ------
  *Borrelia miyamotoi*   79.5°C    106.3%    12.5                1,041                 18.8   1,567   0.85   1.22

*Tm, melting temperature; LOD, limit of detection; LOQ, limit of quantification; GU, genome unit; CV, coefficient of variation*.

DNA Extraction and Purification
-------------------------------

The DNA was extracted without any prior treatment using 300 μl of whole blood with an equal volume of ADNucleis extraction buffer (5 M guanidium thiocyanate, 500 mM TrisHCL, 50 mM EDTA, 20% Tween 20, 20% Triton X-100, 750 μg proteinase K). After incubation for 20 min at 56°C and 15 min at 80°C, the extracted DNA was purified by means of silica magnetic beads and eluted in 250 μl of elution buffer (10 mM TrisHCl, pH 8.5).

Control of the Extraction
-------------------------

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene as an internal control for PCR extraction and inhibition. The extracted samples were first checked with a PCR targeting the GAPDH gene. If the results of this PCR were consistent (Ct of GAPDH below 32), the samples were then analyzed for the other pathogens. The sequence of interest of GAPDH was inserted into a plasmid to be the *B. miyamotoi* target and this plasmid was used as a positive DNA for the validation of GAPDH primers and PCR mix as well as a positive control for subsequent PCRs. The primers used for GAPDH are described in [Table 1](#T1){ref-type="table"}.

Real-Time PCR
-------------

Real-time PCR was carried out in a total volume of 50 μl with a PCR mix containing ADNucleis PCR buffer (20 mM Tris-HCl, 10 mM NH~4~SO~4~, 10 mM KCl, 2 mM Mg2+, 0.1% TritonX-100, pH 8.8), 2 mM of each dNTP, 600 nM of each primer, 1 μl of Evagreen and 5 units of *Taq* polymerase ADNucleis. Twelve μl of extracted samples were amplified.

An initial denaturation step of 5 min at 95°C was followed by 42 cycles of 15 s at 95°C and 40 s at 60°C (hybridization-elongation). The dissociation curves were generated by a last step of 10 min with temperature increments from 75 to 95°C.

Quantification
--------------

Positive samples were quantified using a standard curve obtained by amplifying known and calibrated concentrations of control DNA of the desired targets. Quantification was obtained using the standard curve equation (Ct = a (Log10 \[DNA\]) + b) where "a" is the slope and "b" the intercept of the curve. The results were expressed in genome units (UG) per ml of blood.

Sequencing
----------

The PCR results of some samples were verified by sequencing. A positive sample at the first PCR was amplified again in a second PCR with the same mix and primers. The product of this second PCR was then sent to an external provider for the sequencing of the obtained amplicons. Primers were supplied to the provider. The sequences obtained after sequencing were then compared to the expected sequence of the amplicon, which is specific of the target.

Results {#s3}
=======

Research of the Presence of *B. miyamotoi* by qPCR on Healthy Control Volunteers
--------------------------------------------------------------------------------

The presence of *B. miyamotoi* was searched by qPCR on the control group of 24 healthy asymptomatic students. For all extracted blood samples, a Ct of less than 32 was detected for the GAPDH extraction control, which allowed further investigation. The results showed that none had *B. miyamotoi* infection ([Table 3](#T3){ref-type="table"}).

###### 

Lack of detection of *B. miyamotoi* in the healthy persons of the control group.

                     **PCR inhibition**   **Ct GAPDH values**   **Detection**
  ------------------ -------------------- --------------------- ---------------
  FDC071             No                   29.44                 Not detected
  MCM072             No                   24.46                 Not detected
  MGA073             No                   28.57                 Not detected
  MFA074             No                   28.47                 Not detected
  FBF075             No                   27.7                  Not detected
  MDW076             No                   27.76                 Not detected
  FDT077             No                   30.97                 Not detected
  MAJ078             No                   28.29                 Not detected
  MMC079             No                   28.81                 Not detected
  FMS081             No                   28.08                 Not detected
  MSL082             No                   31.28                 Not detected
  MMD085             No                   31.55                 Not detected
  MPA088             No                   30.57                 Not detected
  FVA089             No                   29.98                 Not detected
  MGW092             No                   31.17                 Not detected
  FDN093             No                   29.15                 Not detected
  MBA094             No                   31.87                 Not detected
  FFS095             No                   28.32                 Not detected
  FBA096             No                   28.7                  Not detected
  FGA098             No                   28.89                 Not detected
  MACA101            No                   26.54                 Not detected
  MLS103             No                   30.83                 Not detected
  FLH105             No                   31.77                 Not detected
  FLL106             No                   28.44                 Not detected
  Positive control   No                   22.83                 Detected
  Negative control   No                   0                     Not detected

*B. miyamotoi was searched by qPCR on a control group of 24 healthy asymptomatic students. All analyzed bloods were negative*.

Results of Analyses on Symptomatic Patients
-------------------------------------------

After the confirmation of the absence of *B. miyamotoi* in the group of healthy people, analyses were performed on the second group of symptomatic patients. Out of a total of 824 analyses, 43 samples were detected positive by qPCR for *B. Miyamotoi* ([Figure 2](#F2){ref-type="fig"}), which corresponds to 5.22% of the patients. Of these 43 samples, *B. miyamotoi* could be quantified in 21 cases. In the remaining 22 cases, *B. miyamotoi* concentration was below the limit of quantification ([Table 4](#T4){ref-type="table"}).

![An example of PCR curves obtained for sample 5589. The positive control well shows a Ct of 25 with a specific Tm of 79°C. Sample 5589 is amplified with a Ct value of 35 and the same specific Tm of 79°C. The negative control well shows no Ct and no Tm.](fmed-07-00055-g0002){#F2}

###### 

Results and quantification of samples detected positive for *B. Miyamotoi*.

  **N**   **ADNucleis ID**   **PCR results**   **Ct**   **Tm (^**°**^C)**   **Quantification GU/PCR**   **Quantification GU/ml**   **Comments**
  ------- ------------------ ----------------- -------- ------------------- --------------------------- -------------------------- -------------------------------
  5       6107               Detected (LOD)    36.87    78.3                NA                          NA                         Detected but not quantifiable
  7       5557               Detected (LOD)    36.74    78.6                NA                          NA                         Detected but not quantifiable
  8       5113               Detected (LOD)    35.73    78.6                NA                          NA                         Detected but not quantifiable
  9       5914               Detected          34.76    78.8                4.0E+01                     2.79E+03                   --
  10      6072               Detected (LOD)    39.4     79                  NA                          NA                         Detected but not quantifiable
  11      6129               Detected (LOD)    39.39    79                  NA                          NA                         Detected but not quantifiable
  12      6273               Detected (LOD)    36.91    78.4                NA                          NA                         Detected but not quantifiable
  13      6591               Detected          25.92    79                  2.4E+04                     1.68E+06                   --
  14      6594               Detected          31.59    78.6                1.5E+04                     1.07E+06                   --
  15      6864               Detected (LOD)    33.82    78.2                1.99E+00                    1.38E+02                   Detected but not quantifiable
  16      6784               Detected (LOD)    32.85    78.3                4.08E+00                    2.83E+02                   Detected but not quantifiable
  17      7086               Detected (LOD)    37.22    78.5                2.15E+01                    1.49E+03                   Detected but not quantifiable
  18      6527               Detected          34.26    79.5                2.7E+03                     1.89E+05                   
  19      6749               Detected          29.91    79.7                4.58E+04                    3.18E+06                   --
  20      6213               Detected (LOD)    39.66    79                  NA                          NA                         Detected but not quantifiable
  21      6630               Detected (LOD)    38.19    78.5                1.13E+01                    7.88E+02                   Detected but not quantifiable
  22      6362               Detected          34.41    79.5                2.5E+03                     1.71E+05                   --
  23      5815               Detected          30.13    79.1                4.0E+04                     2.76E+06                   --
  24      6585               Detected          34.9     79                  1.8E+03                     1.25E+05                   --
  25      7147               Detected          36.49    78.2                9.47E+02                    6.58E+04                   --
  26      6136               Detected (LOD)    37.52    78.4                NA                          NA                         Detected but not quantifiable
  36      6235               Detected (LOD)    39.02    79.5                NA                          NA                         Detected but not quantifiable
  37      6228               Detected (LOD)    35.76    79                  NA                          NA                         Detected but not quantifiable
  38      6231               Detected (LOD)    36.56    79                  NA                          NA                         Detected but not quantifiable
  39      6301               Detected (LOD)    38.53    79                  NA                          NA                         Detected but not quantifiable
  40      6407               Detected (LOD)    38.91    78.7                NA                          NA                         Detected but not quantifiable
  41      6596               Detected          34.01    79.5                3.2E+03                     2.22E+05                   --
  42      5589               Detected          34.13    79.5                3.0E+03                     2.06E+05                   --
  43      6600               Detected          34.53    79.5                2.3E+03                     1.59E+05                   --
  44      6603               Detected          34.61    79.5                2.2E+03                     1.51E+05                   --
  45      6524               Detected          37.98    78.9                2.4E+02                     1.69E+04                   --
  47      6615               Detected (LOD)    36.51    79                  NA                          NA                         Detected but not quantifiable
  48      6734               Detected          28.73    78.5                9.9E+04                     6.84E+06                   --
  49      6735               Detected          33.04    79                  6.0E+03                     4.17E+05                   --
  50      6733               Detected          31.49    79.1                1.6E+04                     1.14E+06                   --
  51      6985               Detected (LOD)    34.04    78.2                1.69E+00                    1.17E+02                   Detected but not quantifiable
  52      6992               Detected (LOD)    33.25    78.3                3.03E+00                    2.11E+02                   Detected but not quantifiable
  53      7159               Detected          37.13    78.5                6.24E+02                    4.33E+04                   --
  54      7160               Detected          37.43    78.5                5.13E+02                    3.56E+04                   --
  55      6578               Detected          33.99    79.5                7.0E+01                     4.87E+03                   --
  56      6576               Detected (LOD)    35.64    79.5                NA                          NA                         Detected but not quantifiable
  60      7099               Detected (LOD)    34.28    78.3                1.41E+00                    9.81E+01                   Detected but not quantifiable
  61      5430               Detected          32.91    78.5                2.3E+02                     1.27E+04                   --

*In 43 blood samples, B. miyamotoi was detected, i.e., 5.22% of the samples analyzed. For 22 samples, the detection was inferior to the limit of quantification of the B. miyamotoi PCR kit thus these samples could not be quantified. These 22 samples are said to be positive in limit of detection (LOD). For 21 samples, quantification was possible. The melting temperature of the B. miyamotoi positive control is 79°C and the tolerance range for the B. miyamotoi positive Tm is 79 ± 1.5°C. The melting temperatures of the amplicons coming from the detected samples are between 78.3 and 79.5°C. These amplicons are due to specific amplifications produced by the B. miyamotoi primers*.

Sequencing of the Amplicons Obtained
------------------------------------

In order to confirm the specificity of the *B. miyamotoi*amplicons in the positive samples, eight positive and five negative samples (13 in total) were selected and subjected to DNA sequencing. Negative samples were sequenced in order to confirm that the readings retrieved were specific of positive samples and not a sequencing artifact. Negative samples had \<20% similarity to the expected amplified sequence with no long runs of similar nucleotides ([Figure 3A](#F3){ref-type="fig"}), while all positive samples showed greater than 60% similarity, even up to more than 90% for some amplification results (91% for sample number), with high number of similar consecutive nucleotides ([Figures 3B,C](#F3){ref-type="fig"}). Giving the shortness of the amplified sequence (94 bp), as for any sequencing, the beginning (and sometimes a few base pairs at the end) of the sequence is often not available (used by the primer which is not sequenced) and accounts for the fact that only 60% of some of the sequenced amplicons are read.

![**(A)** Graph of the percentage of identical base pairs for the detected and undetected samples for *B. miyamotoi* PCR. The percentage of identical sequenced bases is \>60% for the detected samples which display long runs of identical bases **(B)** and \<20% for the samples not detected in PCR with no long runs of identical nucleotides **(C)**. The sequence of interest of *B. miyamotoi* is a very short sequence (94bp). When sequencing small sequences, the first bases may not be recognized by the sequencer because of the brevity of the sequence, which explains why for some positive samples, sequencing only returns 60% of the bases of the sequence.](fmed-07-00055-g0003){#F3}

Clinical Charts of Symptomatic Patients
---------------------------------------

Among the 43 patients with a positive PCR, 31 filled the questionnaire with their physician. Out of the 31 reported cases, 11 had their place of residence in Bretagne or the Loire Valley (West); the others were spread throughout the territory with a slight predominance for the South-West and the Rhône-Alpes region (South-East).

The duration of signs and symptoms divided the patients into two groups. For six patients, the duration of signs and symptoms was less than one year, while for 25 patients, signs and symptoms persisted on the long term ([Table 5](#T5){ref-type="table"}). Two patients have been sick for almost 30 years, two other patients for at least 20 years, the remaining patients between 1 and 19 years.

###### 

Clinical signs and symptoms of 31 patients[^\*^](#TN1){ref-type="table-fn"} with a PCR, performed from a blood sample, positive for *Borrelia miyamotoi*.

                                                    **Number of patients (%)**   **Description**                                                 **Number of patients (%)**
  ------------------------------------------------- ---------------------------- --------------------------------------------------------------- ----------------------------
  Duration of signs and symptoms                                                 Less than 1 year Long term[^\*\*^](#TN2){ref-type="table-fn"}   6 (19.4) 25 (80.6)
  **Signs and symptoms**                                                                                                                         
  Erythema migrans                                  5 (16.1)                                                                                     
  Asthenia                                          31 (100)                     Moderate                                                        10 (32.2)
                                                                                 Strong                                                          21 (67.8)
  Joint pain (often migrating)                      31 (100)                     Moderate                                                        9 (29)
                                                                                 Strong                                                          22 (71)
  Neurocognitive disorders                          31 (100)                     Loss of concentration, attention, memory and/or speech          
  Sleeping disorders                                31 (100)                                                                                     
  Other pains                                                                    Myalgia                                                         25 (80.6)
                                                                                 Including muscle cramps                                         16 (51.6)
                                                                                 Cephalalgia (strong)                                            20 (64.5)
  Thermoregulation disorders and associated signs                                Chilliness                                                      18 (58)
                                                                                 Hot flushes                                                     16 (51.6)
                                                                                 Sweats (mainly at night)                                        15 (48.4)
                                                                                 Relapsing fever                                                 11 (35)
  Respiratory symptoms                                                           Chest tightness/lack of air                                     13 (41.9)
                                                                                 Dyspnea                                                         6 (19.4)
  Balance disorders/malaises                                                     Repeated falls                                                  3 (9.7)
                                                                                 Repeated malaises                                               2 (6.5)
  Visual disturbances                                                            Amputation of the visual field                                  1 (3.2)
                                                                                 Diplopia                                                        1 (3.2)
  Other neurologic disorders                                                     Parsonage-Turner syndrome                                       2 (6.5)
                                                                                 Multiple sclerosis                                              1 (3.2)
                                                                                 Manic depressive psychosis                                      1 (3.2)

*These 31 patients are those, among the 43 patients of the study, who fulfilled with their physician a questionnaire*.

*For six patients, the duration of signs and symptoms was less than one year, while for 25 patients, average duration of signs and symptoms was 9 years, with a range from 1 to 30 years. Two patients have been sick for almost 30 years, two other patients for at least 20 years, the remaining patients between 1 and 19 years*.

The results of the Lyme borreliosis ELISA test (commercial tests, performed in city laboratories) which is based on three species of the *B. Burgdorferi s.l*. complex (*B. burgdorferi s.s*., *B. afzelli, B. garini*), are negative for 19 patients (76% of 26 informed cases), doubtful in three cases, positive in three cases, and not informed in six cases. Western-blot was negative in nine cases (50% of 18 informed cases), positive in nine cases (including three formerly positive and one doubtful with previous ELISA test). For 13 patients, Western-blot was not performed (eight cases) or no result was informed (five cases).

Erythema migrans, a sign specific for Lyme disease, was not frequent ([Table 5](#T5){ref-type="table"}).

Other recorded clinical signs and symptoms are reported in [Table 5](#T5){ref-type="table"}. Asthenia was constant and was usually happening quite abruptly, corresponding to a change of life for patients, in their personal, professional and sport activities. The asthenia intensity was graded with a 0--5 scale, and reported as "moderate" (score of 1--3) or "strong" (score of 4 or 5). The cephalalgia intensity was graded with a 0--5 scale, and reported as "moderate" (score of 1--3) or "strong" (score of 4 or 5). Some patients with neurocognitive disorders were unable to answer questions correctly. In these cases, it is their family members or relatives who answered for them.

A significant proportion of patients experienced signs suggesting thermoregulation disorders, including episodes of relapsing fever, an interesting fact since *B. miyamotoi* belongs to a group responsible for relapsing fever.

Discussion {#s4}
==========

*B. miyamotoi* belongs to the relapsing fever group of pathogenic *Borrelia*. Rather few cases of *B. miyamotoi* infection were identified in humans. There is a debate about the clinical picture of the disease. It can be responsible for relapsing fever; however some clinical cases were more similar to Lyme borreliosis, including some cases with erythema migrans. The present study, conducted in France, is the largest case series of *B. miyamotoi* infection detected in patients suffering from long term persistent syndrome. It complements the Russian study by Karan et al. published in 2018 ([@B28]), which was conducted at the early stage on patients presenting with acute symptoms after a tick bite. The results of both studies suggest that *B. miyamotoi* is more frequent in humans than previously thought. We provide a gross description of the clinical signs and symptoms and the duration of the disease. However the lack of power of the clinical part of the study does not allow a definite conclusion about a precise clinical description. *B. miyamotoi* has a particular position in the genus *Borrelia*. No serology is available in routine. The sensitivity of PCR for the species belonging to the *B. burfdorferi s.l*. complex appears to be rather low, especially in blood. The sensitivity of PCR for *B. miyamotoi* is not known. The species *B. miyamotoi* may also suffer from a deficit of detection. PCR may become a useful means for the detection of *Borrelia*, amplifying the *fla* gene for flagellin, specific of *Borrelia* species. The *fla* gene is present in all *Borrelia* species with several conserved portions between the different *Borrelia species*. The choice of the sequence of interest should depend on the chosen target i.e., *B. burgdorferi sensu stricto* or *sensu lato*. As the *fla* gene is also present in the genome of *B. miyamotoi*, it is possible that *B. miyamotoi* could have been detected and included in the *B. Burgdorferi s.l*. complex. The use of a kit specific for *B. miyamotoi* target probably favored our isolation. *B. miyamotoi* is a species apart, pathogenic and probably non-commensal as suggested by the fact that the healthy students of the University of Angers are not infected, while being in a rural area rich in ticks.

As evidenced in the publication by Reiter et al. ([@B30]) and the sequence alignment, the sequence fragment used for the detection of *B. miyamotoi* in the blood of the French patients tested is strongly homologous to other European strains of *B. miyamotoi* found in patients (KJ847051.1, AB824855.1, AB824730.1), showing only two nucleotides differences between sequences; differences which does not affect detection by PCR (see [Figure 4](#F4){ref-type="fig"}). The *glpQ* gene was chosen for its specificity as it is, to the best of our current knowledge, only present in *B. miyamotoi* strains. Thus, the detection of a said gene is indicative of the presence of the pathogen. Additional genes often show lack of specificity, especially the 16S RNA or *flaB* genes, which are highly conserved in all *Borrelia* species, including those of the relapsing fever group. Indeed, sequencing of really short PCR fragments is often challenging as the first 20 or so nucleotides (the primer) are already "lost" due to the intrinsic nature of sequencing which does not "read" the primer used. Our claim is not with the percentage of similarity *per se*, our claim is in the consecutiveness of those homologous nucleotides. Forty identical consecutive bases, even in a 94 bases long fragment, deriving from a gene is specific of a pathogen.

![Alignment of the *Borrelia miyamotoi* French strain with the other European *Borrelia miyamotoi* strains (KJ847051.1, AB824855.1, AB824730.1). The sequences show a single nucleotide difference that does not affect the PCR and the PCR efficiency.](fmed-07-00055-g0004){#F4}

The sequencing carried out shows that the amplicon obtained by PCR corresponds, for more than 60% and up to 90% of the purine and pyrimidine bases, to the desired target sequence specific for the *B. miyamotoi* species.

During the study period, *B. miyamotoi* was found with a high frequency (5.22%) compared to the other *Borrelia* species, i.e., *B. burgdorferi s.l*. (including *B. burgdorferi s.s*. *, B. garinii, B*. *afzelli, B. bissettii, B. spielmani, B. kurtenbachi*): 0.73% and *B. hermsii*: 0.36% (data not shown).

This pilot study, conducted in patients from various regions in France, suggests that *B. miyamotoi* infection could be more frequent in humans than previously thought and perhaps more frequent than other species of *Borrelia*, especially those classically responsible for Lyme disease. The signs and symptoms of persistent polymorphic syndrome possibly due to a tick bite are close to those described as post-treatment Lyme disease syndrome. Erythema migrans was observed in 16.1% of the patients, but data are insufficient to rule out a previous infection with *B. burgdorferi s.l*. However the responsibility of *B. miyamotoi* in some cases of erythema migrans is probable since, in the study looking at the early stage of the tick-borne infection, 3% of patients with an erythema migrans had a positive blood PCR for *B. miyamotoi* ([@B28]). Our data suggest that the disease may be persistent, even on the long term and that this species of *Borrelia* may not cross-react with *B. burgdorferi* serology. Asthenia, joint pain, neurocognitive disorders and sleep disorders were reported by all patients. Episodes of relapsing fever were observed in 35.5% of the cases. A large prospective study is needed to further describe this infection in well-defined populations.

In conclusion, among French patients suffering from a persistent polymorphic syndrome possibly due to a tick bite (SPPT), a syndrome close to post-treatment Lyme disease syndrome (PTLDS), 43 out of 824 (5.22%) had *B. miyamotoi*in their blood identified by specific real-time PCR, including 22 cases at the detection limit and 21 quantifiable cases. This is the first detection of this bacterial species in humans in France. Sequencing showed the specificity of the detected DNA as *B. miyamotoi*. This study highlights that the lack of detection of *B. miyamotoi* is not due to the absence of this particular species of *Borrelia* in France, but rather because this species was not sought out. Clinical studies designed to evaluate the correlation of PCR results with clinical signs and symptoms should be done to better investigate patients suffering from persistent polymorphic signs and symptoms of unclear origin.
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